查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1832217

抗病毒药物市场（按适应症、药物类别、给药途径、分销管道和最终用户划分）—2025-2032 年全球预测

Antiviral Drugs Market by Indication, Drug Class, Route Of Administration, Distribution Channel, End User - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 190 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年抗病毒药物市场规模将成长至 1,008.3 亿美元，复合年增长率为 6.73%。

主要市场统计数据
预测年份（2024年） 598.4亿美元
基准年（2025年） 638.1亿美元
预测年份（2032年） 1008.3亿美元
复合年增长率（%） 6.73%

简明介绍当前抗病毒治疗领域，整合科学进步、临床压力和对策略领导者的系统性影响

抗病毒领域正处于曲折点，治疗创新、医疗服务模式的转变以及不断变化的监管环境交织在一起，重塑研发和商业性模式。本执行摘要按适应症、药物类别和分销管道总结了最重要的趋势，并将这些趋势转化为对临床团队、商业领导者和供应链高管的策略启示。我们的目标是将复杂的跨学科资料浓缩成一份可操作的演示文稿，供那些需要平衡短期业务重点和长期研发路径的领导者参考。

为了确保与各相关人员群体的相关性，本分析重点关注临床未满足需求、技术可行性以及系统压力，这些因素正在重新定义抗病毒疗法的开发和交付方式。分析整合了科学发展轨迹（例如抗病毒治疗方法和诊断技术的进步）与实际考虑（例如采购方法、付款人参与度和门诊治疗实用化）。自始至终，分析都着重于影响患者可及性、治疗价值以及应对供应中断的韧性的决策，为规划和投资决策提供简明而细緻的方向。

深入分析从根本上改变抗病毒药物开发和商业化轨蹟的科学、监管和供应创新

变革性转变正在改变抗病毒药物研发和给药领域的竞争格局和临床前景。生物和核酸技术正从概念验证转向有效的治疗策略，推动着旨在延长缓解持续时间、提高依从性和针对机制介入的计画。同时，诊断技术正在与治疗技术融合，从而实现早期检测和「检测即治疗」模式，这正在影响临床试验设计和商业性获取策略。

监管途径正在调整，以适应高需求领域的加速发展，支付方也越来越多地将报销与现实世界的疗效和健康经济价值挂钩。数位健康工具正在整合到病患监测和依从性计划中，支持分散式护理模式，并在临床适用的情况下将药物使用从住院环境中转移出去。灵活的生技药品产能和模组化製造技术等製造创新正在缩短前置作业时间，并实现在地化供应链。总的来说，这些转变正在创造一种新格局，敏捷性、跨部门伙伴关係和快速的证据生成将决定谁能将科学前景转化为持续的临床和商业性成功。

全面评估2025 年美国关税改革如何为供应链弹性和製造在地化带来直接的采购压力和策略诱因。

美国关税调整将于2025年生效，其累积效应将对参与抗病毒治疗的机构的采购、製造和临床运作带来多方面压力。对关键化学中间体和某些成品征收的进口关税将增加依赖全球供应网络的公司的到岸成本，促使采购团队重新评估筹资策略，并考虑近岸外包或合格的替代供应商以保持连续性。这种向供应商多元化的转变通常需要大量的前置作业时间和资本投入，以确保获得替代製造合作伙伴的资格并确保符合监管品质标准。

诊所和医院系统面临采购价格波动加剧的问题，这会影响其采购週期和库存政策。一些医疗机构正在扩大库存缓衝，而另一些机构则正在协商长期采购协议以缓解波动。对开发商而言，关税带来的成本压力可能会改变其在何处以及如何扩大生产规模的考量，儘管本地营运成本较高，但受跨境关税影响较小的区域生产基地可能会受到青睐。关税也会影响合约製造机构的动态，因为对合格国内或区域产能的需求增加会在交付时间和定价方面带来竞争压力。

新兴的政策因应措施和私部门为抵销影响而采取的策略包括：有针对性的供应协议、加强垂直整合以及关键活性药物原料药的策略性储备。这些调整对下游领域也产生了影响，例如临床试验材料的供应速度、与付款方和采购方进行价格谈判的成本基础，以及优先考虑那些不需要更复杂投入的治疗方案。整体而言，关税环境正在加速向供应链弹性和冗余度的策略转变，同时也凸显了透过流程创新和提高製造效率来控製成本的重要性。

拥有有效策略的公司：对适应症、治疗层级、给药途径、分销管道和最终用户动态的详细细分洞察推动了差异化策略

根据适应症，我们揭示了针对B肝、C肝、单纯疱疹病毒、爱滋病毒、流感病毒和呼吸道症候群病毒的临床需求和商业策略的差异化途径。乙肝计画越来越注重持续的病毒抑制和功能性治癒策略，以推动长期安全性和生物标记的开发；而丙肝计画则强调便捷的治疗方案和可及性模式，以支持广泛的病例检测。单纯疱疹病毒的管理仍然着重于高风险族群的发病控制和预防；爱滋病毒研究则在长效製剂、以治癒为导向的治疗方法与成熟的慢性病照护模式之间寻求平衡。流感和呼吸道融合细胞病毒计画优先考虑季节性治疗和快速诊断，以优化治疗和预防的时机。

以药物类别划分，优先考虑的药物包括融合抑制剂、整合酶抑制剂、非核苷类逆转录酶抑制剂、核苷类似物和蛋白酶抑制剂。整合酶抑制剂和融合抑制剂因其新颖的抗药性特性和优异的耐受性而备受关注，而核苷类似物和蛋白酶抑制剂仍然是成熟方案的基石，需要谨慎的生命週期管理。非核苷类逆转录酶抑制剂仍在接受评估，以改善其安全性，并探索联合用药策略，从而提高药物的持久性和依从性。

给药途径—吸入、注射、口服和外用—决定了病患的依从性、配送物流和临床环境。口服疗法仍然是门诊病人管理和慢性病维持的核心，注射剂和长效製剂有助于提高依从性并减少就诊频率，吸入疗法可为呼吸道病毒提供靶向肺部暴露，而局部製剂仍然适用于粘膜皮肤感染疾病，因为局部给药可提高耐受性。

诊所、医院药局、线上药局和零售药局之间的分销管道动态影响着药物的可及性、报销途径和即时护理决策。诊所和医院药局通常提供复杂的治疗方案和肠外用药，而线上药局和零售药局则提供更方便的口服和局部製剂。最后，终端使用者细分（包括诊所、居家医疗、医院和长期照护机构）凸显了照护环境在治疗方法选择中的重要性。居家医疗和门诊诊所正在推动对易于使用的製剂和简化监测方案的需求，而医院和长期护理机构则需要强大的供应和管理工作流程来应对复杂的治疗方案。

战略区域见解强调监管、临床和製造因素如何影响美洲、欧洲、中东和非洲以及亚太地区的实施选择

区域动态对于确定抗病毒药物研发重点、生产地点和商业化方案至关重要。在美洲，成熟的研究基础设施和广泛的临床试验网络支持快速的转化活动，而政策辩论和付款人框架则影响定价策略和可及性模式。美洲也是长效和先进治疗方法上市的关键市场，其医疗保健体系能够适应复杂的基于价值的协议和上市后证据收集。

欧洲、中东和非洲地区环境复杂，监管协调力道不足，报销格局也各异。欧洲法规结构强调稳健的比较有效性和健康经济证据，鼓励製造商在研发早期就投资于真实世界数据收集和支付方参与。中东和非洲地区在药品可及性方面面临独特的挑战，也为官民合作关係提供了机会，重点是建立生产能力和分销网络，以覆盖服务不足的人群。

亚太地区是一个多元化的地区，拥有快速成长的研发投入、庞大的病患群体和显着的未满足需求，以及新兴的生产能力。亚太地区的多个经济体正在大力投资小分子和生技药品的生产，优惠的政策奖励也正在加速临床开发吞吐量。该地区的商业策略必须协调多元化的支付系统、波动的患者负担能力，以及数位管道在患者参与和分销中日益增强的作用。任何地区成功的计画都必须将证据产生、供应链设计和商业模式与当地监管期望和医疗保健服务的实际情况相结合。

从公司层级对创新、製造策略和伙伴关係模式的实用观点，推动抗病毒药物开发和商业化的竞争优势

抗病毒治疗领域的企业策略正围绕着几个影响深远的优先事项展开，包括推动差异化治疗方法、确保韧性生产能力以及在整个生态系统中建立合作伙伴关係。领先的开发商正在平衡内部创新与标靶授权合约和共同开发契约，以加速获取新机制并管理技术风险。投资能够以模组化方式调整病毒标靶的平台技术，可以加快从药物发现到临床候选药物的转化，各公司越来越优先考虑那些能够明确提高依从性并减少密集监测需求的资产。

在营运方面，企业正在不断整合其供应链，透过选择性垂直迁移和策略製造联盟来扩大产能，并降低跨境成本衝击的风险。在商业方面，他们正在试验基于价值的合约和付款人合作伙伴关係，以使长期成果与报销结构保持一致，而专业的商业化团队则专注于差异化管道，例如医院处方集和专科药房。同时，大型跨国製药公司拥有规模优势、监管专业知识以及全球分销网络的管道。对于所有类型的公司而言，成功越来越取决于其能否将临床差异化展现为患者和系统价值，并透过复杂的护理路径将这种价值实用化。

针对研发优先事项、製造弹性、付款人参与度和商业性执行提出具体、优先的建议，以确保持续的抗病毒药物成功

产业领导者应优先考虑一系列切实可行的措施，使研发选择与商业性执行和供应链韧性相协调。首先，加快对长效、有针对性的给药方式的投资，这些方式能够显着提高依从性并减轻系统负担，并将临床开发计划与收集真实世界证据以支持报销的稳健计划相结合。其次，透过确保区域合作伙伴和灵活的製造外包实现生产布局多元化，并结合针对关税中断和投入短缺的情境规划，最大限度地降低临床试验和商业供应的风险。

第三，制定整合诊断和远端医疗途径的上市策略，以快速识别合格治疗条件的患者，并减少开始治疗的障碍。第四，儘早与付款方沟通，明确证据要求，并探索基于结果的、风险共担和回报共用的报销结构。第五，建立策略联盟，将平台技术与商业化专业知识结合，例如透过共同开发、授权或有针对性的收购来填补能力缺口。第六，投资数位化病患援助项目，以提高服药依从性，取得结果数据，并降低医疗保健总成本。最后，将永续性纳入采购和製造决策，以减少地缘政治和关税压力的影响，同时满足相关人员对韧性和负责任的企业营运日益增长的期望。

对多方法调查方法的透明解释，该方法结合了专家访谈、监管和科学评论以及情境分析，以检验可行的见解

本执行摘要所依据的研究采用多方法论，结合专家的初步研究、二手文献、监管备案文件和技术资料来源，以提供全面且检验的见解。初步意见包括与临床实验研究人员、供应链经理、监管专家和商业行业领袖进行的结构化访谈，以提供有关营运挑战、临床重点和付款人期望的底层观点。二次审查涵盖同侪审查文献、临床试验註册中心、专利态势和官方监管决策，以绘製科学趋势和开发平臺。

分析方法包括定性主题综合（用于识别重复出现的策略主题）、比较政策分析（用于确定各地区法规的影响）以及情境规划（用于评估供应链和关税的影响）。品质保证透过以下方式实现：透过文件检验对访谈结果进行交叉验证，并将中期主题提交给独立专家小组征求回馈。调查方法认识到水平扫描和专家访谈的固有局限性，包括受访者抽样偏差的可能性以及临床研究的快速发展性。这些限制透过多元化的利害关係人相关人员和反覆的检验週期相关人员。由此得出的洞察优先考虑稳健性和实际相关性，以帮助决策者将短期营运需求与长期检验目标结合。

最终整合关键策略重点，将抗病毒治疗的科学前景转化为持续的临床和商业性成功

总而言之，抗病毒疗法正经历一个由技术发展势头、供应链复杂性不断增加以及市场准入要求不断演变的时期。科学进步为透过长效药物和标靶治疗方法改善患者预后提供了清晰的途径，但成功将取决于自适应製造策略、整合诊断和成熟的支付方参与。区域监管预期和关税驱动的供应动态交互作用凸显了本地化执行和稳健应急计划的重要性。

那些将临床开发与实践价值验证相结合、实现生产和采购方式多样化、并投资于数位化工具以提升依从性和证据采集的开发领导者，将最有能力将科学潜力转化为可及的治疗方法。本摘要中的建议旨在指南当前的营运决策，同时支援长期投资以建立持续的竞争优势。那些兼具战术性反应和战略远见的组织将能够缓解短期干扰，并在不断变化的抗病毒领域中释放永续的成长机会。

目录

第一章 引言

第二章分析方法

第三章执行摘要

第四章 市场概况

第五章 市场洞察

  • 迅速以长效注射抗病毒疗法预防及治疗爱滋病毒
  • 在资源有限的地区扩大丙型肝炎的直接抗病毒治疗
  • 针对保守病毒聚合酵素和蛋白酶的广谱频谱抗病毒药物的开发
  • 在高风险儿科族群中传播针对呼吸道融合病毒（RSV）的单株抗体预防
  • 将人工智慧和机器学习融入抗病毒药物研发和再利用工作
  • 联合抗病毒疗法的出现，对抗药性流感病毒株的疗效增强
  • 为了应对疫情，我们正在加大对整体冠状病毒治疗平台的投资。

第六章：美国关税的累积影响（2025年）

第七章：人工智慧（AI）的累积影响（2025年）

第 8 章：抗病毒药物市场（按适应症）

  • B型肝炎
  • C型肝炎
  • 单纯疱疹
  • HIV
  • 流感
  • 呼吸道融合病毒（RSV）

9. 抗病毒药物市场（依药物类别）

  • 融合抑制剂
  • 整合酶抑制剂
  • 非核苷逆转录酶抑制剂
  • 核苷类似物
  • 蛋白酶抑制剂

第十章抗病毒药物市场（依给药途径）

  • 吸入
  • 注射
  • 口服
  • 外用

第 11 章抗病毒药物市场（按分销管道）

  • 诊所
  • 医院药房
  • 网路药局
  • 零售药局

第 12 章。抗病毒药物市场（按最终用户）

  • 诊所
  • 居家医疗
  • 医院
  • 长期照护机构

第 13 章：抗病毒药物市场（按地区）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第14章 抗病毒药物市场（依类别）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十五章 各国抗病毒药物市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章竞争格局

  • 市占率分析（2024年）
  • FPNV定位矩阵（2024年）
  • 竞争分析
    • Gilead Sciences, Inc.
    • AbbVie Inc.
    • F. Hoffmann-La Roche Ltd
    • Merck & Co., Inc.
    • GlaxoSmithKline plc
    • Pfizer Inc.
    • Johnson & Johnson
    • Bristol-Myers Squibb Company
    • ViiV Healthcare Limited
    • AstraZeneca plc
Product Code: MRR-4358BACA8289

The Antiviral Drugs Market is projected to grow by USD 100.83 billion at a CAGR of 6.73% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 59.84 billion
Estimated Year [2025] USD 63.81 billion
Forecast Year [2032] USD 100.83 billion
CAGR (%) 6.73%

Concise orientation to the current antiviral therapeutics landscape that synthesizes scientific advances, clinical pressures, and system implications for strategic leaders

The antiviral drugs landscape is at an inflection point where therapeutic innovation, shifting care delivery models, and evolving regulatory expectations intersect to reshape research, development, and commercial approaches. This executive summary synthesizes the most consequential developments across indications, drug classes, and distribution channels, and it translates those developments into strategic implications for clinical teams, commercial leaders, and supply chain executives. The goal is to present an actionable condensation of complex, cross-disciplinary data for leaders who must balance near-term operational priorities with longer-term R&D pathways.

To ensure relevance across stakeholder groups, the analysis foregrounds clinical unmet needs, technology enablers, and system pressures that are redefining how antiviral therapies are developed and delivered. The narrative integrates scientific trajectories-such as advances in antiviral modalities and diagnostics-with practical considerations including procurement practices, payer engagement, and the operationalization of outpatient care. Throughout, emphasis is placed on decisions that influence patient access, therapeutic value, and resilience against supply disruptions, providing a concise yet nuanced orientation for planning and investment decisions.

Detailed analysis of the converging scientific, regulatory, and delivery innovations that are fundamentally reshaping development and commercialization pathways for antivirals

A number of transformative shifts are altering the competitive and clinical contours of antiviral therapy development and delivery. Biologic modalities and nucleic acid technologies have moved from proof-of-concept stages into validated therapeutic strategies, fueling programs that aim to deliver longer duration of effect, improved adherence, and targeted mechanism-based interventions. Concurrently, diagnostics are converging with therapeutics to enable earlier detection and test-and-treat paradigms, which in turn influence clinical trial design and commercial access strategies.

Regulatory pathways have adjusted to accommodate accelerated development in high-need areas, and payers are increasingly tying reimbursement to demonstrable real-world outcomes and health economic value. Digital health tools are being integrated into patient monitoring and adherence programs, supporting decentralized care models and shifting utilization away from inpatient settings when clinically appropriate. Manufacturing innovation, including flexible biologics capacity and modular production techniques, is reducing lead times and enabling regionalized supply chains. These shifts collectively create a landscape in which agility, cross-sector partnerships, and rapid evidence generation determine who can translate scientific promise into durable clinical and commercial success.

Comprehensive assessment of how the 2025 United States tariff changes create immediate procurement pressures and strategic incentives for supply chain resilience and manufacturing localization

The cumulative effect of the United States tariff adjustments enacted in 2025 introduces multifaceted pressures across procurement, manufacturing, and clinical operations for organizations engaged in antiviral therapeutics. Import duties on key chemical intermediates and selected finished pharmaceuticals have increased landed costs for firms that rely on global supply networks, prompting procurement teams to reassess sourcing strategies and to explore nearshoring or alternate supplier qualification to maintain continuity. This reorientation toward supplier diversification often requires significant lead time and capital investment to qualify alternate manufacturing partners and to ensure compliance with regulatory quality standards.

Clinics and hospital systems face increased variability in procurement pricing, which in turn affects purchasing cycles and inventory policies; some institutions are extending inventory buffers while others are negotiating longer term purchasing agreements to mitigate volatility. For developers, tariff-driven cost pressures can change the calculus for where and how manufacturing scale-up is executed, potentially favoring regional production hubs that reduce exposure to cross-border duties despite higher local operating costs. The tariffs also influence the dynamics of contract manufacturing organizations, as increased demand for domestic or qualified regional capacity creates competitive pressure on timelines and pricing.

Policy responses and private sector strategies are emerging to offset impacts, including targeted supply agreements, increased vertical integration, and strategic stockpiling for critical active pharmaceutical ingredients. These adjustments have downstream effects on the speed of clinical trial material provisioning, the cost base for pricing negotiations with payers and procurers, and the prioritization of therapeutic pipelines that require fewer complex inputs. In aggregate, the tariff environment accelerates a strategic shift toward resilience and redundancy in supply chains while elevating the importance of cost containment through process innovation and manufacturing efficiency.

In-depth segmentation insights spanning indications, therapeutic classes, administration routes, distribution channels, and end-user dynamics driving differentiated strategies

Segmentation by indication reveals differentiated pathways of clinical need and commercial strategy across Hepatitis B, Hepatitis C, Herpes Simplex, HIV, Influenza, and Respiratory Syncytial Virus. Hepatitis B programs are increasingly focused on durable viral suppression and functional cure strategies, demanding long-term safety and biomarker development, whereas Hepatitis C efforts emphasize simplified regimens and access models that support broad case finding. Herpes Simplex management remains concentrated on episodic control and prophylaxis for high-risk populations, while HIV research balances long-acting formulations and cure-directed approaches alongside established chronic care models. Influenza and Respiratory Syncytial Virus programs prioritize seasonally responsive therapies and rapid diagnostics to optimize timing of treatment and prophylaxis.

When viewed by drug class, priorities vary between Fusion Inhibitors, Integrase Inhibitors, Non-Nucleoside Reverse Transcriptase Inhibitors, Nucleoside Analogues, and Protease Inhibitors. Integrase and fusion inhibitors are attracting interest for novel resistance profiles and tolerability advantages, while nucleoside analogues and protease inhibitors remain foundational for established regimens that require careful lifecycle management. Non-Nucleoside Reverse Transcriptase Inhibitors continue to be evaluated for improved safety profiles and combination strategies that enhance durability and adherence.

Routes of administration, spanning inhalation, injectable, oral, and topical, shape patient adherence, distribution logistics, and clinical setting. Oral therapies remain central for outpatient management and chronic disease maintenance, injectables and long-acting formulations support adherence and reduce clinic visit frequency, inhalation therapeutics offer targeted pulmonary exposure for respiratory viruses, and topical formulations maintain relevance for mucocutaneous infections where localized delivery improves tolerability.

Distribution channel dynamics across clinics, hospital pharmacies, online pharmacies, and retail pharmacies influence access, reimbursement pathways, and point-of-care decisioning. Clinics and hospital pharmacies often handle complex regimens and parenteral products supported by institutional procurement processes, while online and retail pharmacies expand reach and convenience for oral and topical therapies. Finally, end user segmentation that includes clinics, home care, hospitals, and long term care facilities highlights the importance of care setting in therapeutic choice, with home care and outpatient clinics driving demand for user-friendly formulations and simplified monitoring protocols, and hospitals and long term care facilities requiring robust supply and administration workflows for complex regimens.

Strategic regional considerations highlighting how distinct regulatory, clinical, and manufacturing factors in the Americas, Europe Middle East & Africa, and Asia-Pacific shape execution choices

Regional dynamics are central to shaping R&D priorities, manufacturing placement, and commercialization approaches across the antiviral landscape. In the Americas, established research infrastructure and widespread clinical trial networks support rapid translational efforts, while policy debates and payer frameworks influence pricing strategies and access models. The Americas also function as a key market for long-acting and advanced modality launches, with healthcare systems that can absorb complex value-based contracting and post-launch evidence collection.

Europe, the Middle East & Africa present a heterogeneous environment where regulatory harmonization efforts coexist with varied reimbursement landscapes. European regulatory frameworks favor robust comparative effectiveness and health economic evidence, motivating manufacturers to invest in real-world data generation and payer engagement early in development. The Middle East & Africa region presents distinct access challenges and opportunities for public-private partnerships focused on manufacturing capacity building and distribution networks that reach underserved populations.

Asia-Pacific is a diverse region that combines rapidly expanding R&D investment, large patient populations with significant unmet needs, and emerging manufacturing prowess. Several economies within Asia-Pacific are investing heavily in both small molecule and biologics manufacturing, and favorable policy incentives are accelerating clinical development throughput. Commercial strategies in the region must reconcile heterogenous payer systems, variable patient affordability, and the increasing role of digital channels for patient engagement and distribution. Across all regions, successful programs are those that tailor evidence generation, supply chain design, and commercial models to local regulatory expectations and care delivery realities.

Practical company-level perspectives on innovation, manufacturing strategy, and partnership models that are driving competitive advantage in antiviral development and commercialization

Company strategies in antiviral therapeutics are converging on a few high-impact priorities: advancing differentiated modalities, securing resilient manufacturing capacity, and forging collaborative partnerships across the ecosystem. Leading developers are balancing in-house innovation with targeted licensing and co-development agreements that accelerate access to novel mechanisms while managing technical risk. Investment in platform technologies that enable modular adaptation across viral targets is enabling faster transition from discovery to clinical candidate, and companies are increasingly prioritizing assets with clear pathways to improved adherence or reduced need for intensive monitoring.

Operationally, firms are bolstering supply chain integration and expanding capacity through selective vertical moves or strategic manufacturing partnerships to reduce exposure to cross-border cost shocks. Commercially, organizations are experimenting with value-based contracting and payer partnerships that align long-term outcomes with reimbursement structures, while specialist commercialization teams focus on differentiated channels such as hospital formularies and specialty pharmacies. Smaller biotech firms are leveraging nimble development processes and focused proof-of-concept studies to attract partnerships, while larger multinational pharmaceutical companies provide scale, regulatory expertise, and access to global distribution networks. Across company types, success increasingly depends on the ability to translate clinical differentiation into demonstrable patient and system value and to operationalize that value across complex care pathways.

Concrete and prioritized recommendations for R&D prioritization, manufacturing resilience, payer engagement, and commercial execution to drive durable success in antivirals

Industry leaders should prioritize a suite of actionable measures that align R&D choices with commercial execution and supply chain resilience. First, accelerate investment in long-acting and targeted delivery modalities that demonstrably improve adherence and reduce system burden, pairing clinical development plans with robust plans for real-world evidence collection to support reimbursement. Second, diversify manufacturing footprints by qualifying regional partners and flexible contract manufacturers, and incorporate scenario planning for tariff-driven disruptions and input scarcity to minimize risks to clinical trials and commercial supply.

Third, design launch strategies that integrate diagnostics and telehealth pathways, enabling rapid identification of treatment-eligible patients and reducing barriers to initiation. Fourth, engage payers early to define evidence requirements and to explore outcome-based reimbursement structures that share risk and reward. Fifth, cultivate strategic alliances that pair platform technologies with commercialization expertise, whether through co-development, licensing, or targeted acquisitions that fill capability gaps. Sixth, invest in digital and patient support programs that improve adherence, collect outcome data, and reduce the total cost of care. Finally, embed sustainability into procurement and manufacturing decisions to reduce exposure to geopolitical and tariff pressures while meeting growing stakeholder expectations for resilient and responsible operations.

Transparent description of the multi-method research approach combining expert interviews, regulatory and scientific review, and scenario analysis to validate actionable insights

The research underpinning this executive summary draws on a multi-method approach that triangulates primary expert interviews, secondary literature, regulatory filings, and technical data sources to ensure comprehensive and validated insights. Primary inputs included structured interviews with clinical investigators, supply chain managers, regulatory experts, and commercial leaders, providing ground-level perspectives on operational challenges, clinical priorities, and payer expectations. Secondary review encompassed peer-reviewed literature, clinical trial registries, patent landscapes, and public regulatory decisions to map scientific trends and development pipelines.

Analytical methods included qualitative thematic synthesis to identify recurrent strategic themes, comparative policy analysis to discern regional regulatory implications, and scenario planning to evaluate supply chain and tariff impacts. Quality assurance was maintained through cross-validation of interview findings with document review and by presenting interim themes to an independent panel of subject matter experts for feedback. The methodology acknowledges limitations inherent to horizon scanning and expert elicitation, including potential sampling bias in interview subjects and the rapidly evolving nature of clinical research; these limitations were mitigated through diverse stakeholder engagement and repeated validation cycles. The resulting insights prioritize robustness and practical relevance for decision makers seeking to align near-term operational imperatives with longer-term strategic objectives.

Final synthesis of the critical strategic priorities for converting scientific promise into durable clinical and commercial success in antiviral therapeutics

In summation, antiviral therapeutics are entering a period defined by technological momentum, heightened supply chain complexity, and evolving market access requirements. Scientific advances provide clear pathways to improved patient outcomes through longer-acting agents and targeted modalities, yet successful translation depends on adaptive manufacturing strategies, integrated diagnostics, and sophisticated payer engagement. The interplay of regional regulatory expectations and tariff-driven supply dynamics underscores the importance of localized execution and robust contingency planning.

Leaders who align clinical development with pragmatic proofs of value, diversify manufacturing and procurement approaches, and invest in digital tools for adherence and evidence capture will be best positioned to convert scientific potential into accessible therapies. The recommendations contained in this summary are intended to guide immediate operational decisions while supporting longer-term investments that build durable competitive advantage. Organizations that act with both tactical responsiveness and strategic foresight can mitigate near-term disruptions and unlock sustainable growth opportunities in the evolving antiviral landscape.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Rapid adoption of long-acting injectable antiviral therapies for HIV prevention and treatment
  • 5.2. Expansion of direct-acting antiviral regimens for hepatitis C in resource-limited settings
  • 5.3. Development of broad-spectrum antiviral agents targeting conserved viral polymerases and proteases
  • 5.4. Growth of monoclonal antibody prophylactics for respiratory syncytial virus in high-risk pediatric populations
  • 5.5. Integration of artificial intelligence and machine learning in antiviral drug discovery and repurposing efforts
  • 5.6. Emergence of combination antiviral therapies enhancing potency against drug-resistant influenza strains
  • 5.7. Increased investment in pan-coronavirus therapeutic platforms for pandemic preparedness

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Antiviral Drugs Market, by Indication

  • 8.1. Hepatitis B
  • 8.2. Hepatitis C
  • 8.3. Herpes Simplex
  • 8.4. Hiv
  • 8.5. Influenza
  • 8.6. Respiratory Syncytial Virus

9. Antiviral Drugs Market, by Drug Class

  • 9.1. Fusion Inhibitors
  • 9.2. Integrase Inhibitors
  • 9.3. Non Nucleoside Reverse Transcriptase Inhibitors
  • 9.4. Nucleoside Analogues
  • 9.5. Protease Inhibitors

10. Antiviral Drugs Market, by Route Of Administration

  • 10.1. Inhalation
  • 10.2. Injectable
  • 10.3. Oral
  • 10.4. Topical

11. Antiviral Drugs Market, by Distribution Channel

  • 11.1. Clinics
  • 11.2. Hospital Pharmacies
  • 11.3. Online Pharmacies
  • 11.4. Retail Pharmacies

12. Antiviral Drugs Market, by End User

  • 12.1. Clinics
  • 12.2. Home Care
  • 12.3. Hospitals
  • 12.4. Long Term Care Facilities

13. Antiviral Drugs Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Antiviral Drugs Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Antiviral Drugs Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. Gilead Sciences, Inc.
    • 16.3.2. AbbVie Inc.
    • 16.3.3. F. Hoffmann-La Roche Ltd
    • 16.3.4. Merck & Co., Inc.
    • 16.3.5. GlaxoSmithKline plc
    • 16.3.6. Pfizer Inc.
    • 16.3.7. Johnson & Johnson
    • 16.3.8. Bristol-Myers Squibb Company
    • 16.3.9. ViiV Healthcare Limited
    • 16.3.10. AstraZeneca plc

LIST OF FIGURES

  • FIGURE 1. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY INDICATION, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AMERICAS ANTIVIRAL DRUGS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. NORTH AMERICA ANTIVIRAL DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. LATIN AMERICA ANTIVIRAL DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA ANTIVIRAL DRUGS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. EUROPE ANTIVIRAL DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. MIDDLE EAST ANTIVIRAL DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AFRICA ANTIVIRAL DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC ANTIVIRAL DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASEAN ANTIVIRAL DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GCC ANTIVIRAL DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION ANTIVIRAL DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BRICS ANTIVIRAL DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. G7 ANTIVIRAL DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NATO ANTIVIRAL DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. ANTIVIRAL DRUGS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. ANTIVIRAL DRUGS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. ANTIVIRAL DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY HEPATITIS B, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY HEPATITIS B, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY HEPATITIS B, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY HEPATITIS B, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY HEPATITIS B, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY HEPATITIS B, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY HEPATITIS C, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY HEPATITIS C, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY HEPATITIS C, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY HEPATITIS C, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY HEPATITIS C, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY HEPATITIS C, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY HERPES SIMPLEX, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY HERPES SIMPLEX, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY HERPES SIMPLEX, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY HERPES SIMPLEX, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY HERPES SIMPLEX, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY HERPES SIMPLEX, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY HIV, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY HIV, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY HIV, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY HIV, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY HIV, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY HIV, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY INFLUENZA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY INFLUENZA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY INFLUENZA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY INFLUENZA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY INFLUENZA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY INFLUENZA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY RESPIRATORY SYNCYTIAL VIRUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY RESPIRATORY SYNCYTIAL VIRUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY RESPIRATORY SYNCYTIAL VIRUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY RESPIRATORY SYNCYTIAL VIRUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY RESPIRATORY SYNCYTIAL VIRUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY RESPIRATORY SYNCYTIAL VIRUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY FUSION INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY FUSION INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY FUSION INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY FUSION INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY FUSION INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY FUSION INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY INTEGRASE INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY INTEGRASE INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY INTEGRASE INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY INTEGRASE INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY INTEGRASE INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY INTEGRASE INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY NON NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY NON NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY NON NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY NON NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY NON NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY NON NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY NUCLEOSIDE ANALOGUES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY NUCLEOSIDE ANALOGUES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY NUCLEOSIDE ANALOGUES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY NUCLEOSIDE ANALOGUES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY NUCLEOSIDE ANALOGUES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY NUCLEOSIDE ANALOGUES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY PROTEASE INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY PROTEASE INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY PROTEASE INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY PROTEASE INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY PROTEASE INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY PROTEASE INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY INHALATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY INHALATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY INHALATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY INHALATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY INHALATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY INHALATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY INJECTABLE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY INJECTABLE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY ORAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY ORAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY ORAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY ORAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY TOPICAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY TOPICAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY TOPICAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY TOPICAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY TOPICAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY TOPICAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY HOME CARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY HOME CARE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY HOME CARE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY HOME CARE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY HOME CARE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY HOME CARE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY LONG TERM CARE FACILITIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY LONG TERM CARE FACILITIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY LONG TERM CARE FACILITIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY LONG TERM CARE FACILITIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY LONG TERM CARE FACILITIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY LONG TERM CARE FACILITIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 155. AMERICAS ANTIVIRAL DRUGS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 156. AMERICAS ANTIVIRAL DRUGS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 157. AMERICAS ANTIVIRAL DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 158. AMERICAS ANTIVIRAL DRUGS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 159. AMERICAS ANTIVIRAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 160. AMERICAS ANTIVIRAL DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 161. AMERICAS ANTIVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 162. AMERICAS ANTIVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 163. AMERICAS ANTIVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 164. AMERICAS ANTIVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 165. AMERICAS ANTIVIRAL DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 166. AMERICAS ANTIVIRAL DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 167. NORTH AMERICA ANTIVIRAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 168. NORTH AMERICA ANTIVIRAL DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 169. NORTH AMERICA ANTIVIRAL DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 170. NORTH AMERICA ANTIVIRAL DRUGS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 171. NORTH AMERICA ANTIVIRAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 172. NORTH AMERICA ANTIVIRAL DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 173. NORTH AMERICA ANTIVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 174. NORTH AMERICA ANTIVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 175. NORTH AMERICA ANTIVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 176. NORTH AMERICA ANTIVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 177. NORTH AMERICA ANTIVIRAL DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 178. NORTH AMERICA ANTIVIRAL DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 179. LATIN AMERICA ANTIVIRAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 180. LATIN AMERICA ANTIVIRAL DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 181. LATIN AMERICA ANTIVIRAL DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 182. LATIN AMERICA ANTIVIRAL DRUGS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 183. LATIN AMERICA ANTIVIRAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 184. LATIN AMERICA ANTIVIRAL DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 185. LATIN AMERICA ANTIVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 186. LATIN AMERICA ANTIVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 187. LATIN AMERICA ANTIVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 188. LATIN AMERICA ANTIVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 189. LATIN AMERICA ANTIVIRAL DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 190. LATIN AMERICA ANTIVIRAL DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 191. EUROPE, MIDDLE EAST & AFRICA ANTIVIRAL DRUGS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 192. EUROPE, MIDDLE EAST & AFRICA ANTIVIRAL DRUGS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 193. EUROPE, MIDDLE EAST & AFRICA ANTIVIRAL DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 194. EUROPE, MIDDLE EAST & AFRICA ANTIVIRAL DRUGS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 195. EUROPE, MIDDLE EAST & AFRICA ANTIVIRAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 196. EUROPE, MIDDLE EAST & AFRICA ANTIVIRAL DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 197. EUROPE, MIDDLE EAST & AFRICA ANTIVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 198. EUROPE, MIDDLE EAST & AFRICA ANTIVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 199. EUROPE, MIDDLE EAST & AFRICA ANTIVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 200. EUROPE, MIDDLE EAST & AFRICA ANTIVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 201. EUROPE, MIDDLE EAST & AFRICA ANTIVIRAL DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 202. EUROPE, MIDDLE EAST & AFRICA ANTIVIRAL DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 203. EUROPE ANTIVIRAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 204. EUROPE ANTIVIRAL DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 205. EUROPE ANTIVIRAL DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 206. EUROPE ANTIVIRAL DRUGS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 207. EUROPE ANTIVIRAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 208. EUROPE ANTIVIRAL DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 209. EUROPE ANTIVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 210. EUROPE ANTIVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 211. EUROPE ANTIVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 212. EUROPE ANTIVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 213. EUROPE ANTIVIRAL DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 214. EUROPE ANTIVIRAL DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 215. MIDDLE EAST ANTIVIRAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 216. MIDDLE EAST ANTIVIRAL DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 217. MIDDLE EAST ANTIVIRAL DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 218. MIDDLE EAST ANTIVIRAL DRUGS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 219. MIDDLE EAST ANTIVIRAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 220. MIDDLE EAST ANTIVIRAL DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 221. MIDDLE EAST ANTIVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 222. MIDDLE EAST ANTIVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 223. MIDDLE EAST ANTIVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 224. MIDDLE EAST ANTIVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 225. MIDDLE EAST ANTIVIRAL DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 226. MIDDLE EAST ANTIVIRAL DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 227. AFRICA ANTIVIRAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 228. AFRICA ANTIVIRAL DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 229. AFRICA ANTIVIRAL DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 230. AFRICA ANTIVIRAL DRUGS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 231. AFRICA ANTIVIRAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 232. AFRICA ANTIVIRAL DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 233. AFRICA ANTIVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 234. AFRICA ANTIVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 235. AFRICA ANTIVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 236. AFRICA ANTIVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 237. AFRICA ANTIVIRAL DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 238. AFRICA ANTIVIRAL DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 239. ASIA-PACIFIC ANTIVIRAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 240. ASIA-PACIFIC ANTIVIRAL DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 241. ASIA-PACIFIC ANTIVIRAL DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 242. ASIA-PACIFIC ANTIVIRAL DRUGS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 243. ASIA-PACIFIC ANTIVIRAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 244. ASIA-PACIFIC ANTIVIRAL DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 245. ASIA-PACIFIC ANTIVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 246. ASIA-PACIFIC ANTIVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 247. ASIA-PACIFIC ANTIVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 248. ASIA-PACIFIC ANTIVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 249. ASIA-PACIFIC ANTIVIRAL DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 250. ASIA-PACIFIC ANTIVIRAL DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 251. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 252. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 253. ASEAN ANTIVIRAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 254. ASEAN ANTIVIRAL DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 255. ASEAN ANTIVIRAL DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 256. ASEAN ANTIVIRAL DRUGS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 257. ASEAN ANTIVIRAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 258. ASEAN ANTIVIRAL DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 259. ASEAN ANTIVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 260. ASEAN ANTIVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 261. ASEAN ANTIVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 262. ASEAN ANTIVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 263. ASEAN ANTIVIRAL DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 264. ASEAN ANTIVIRAL DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 265. GCC ANTIVIRAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 266. GCC ANTIVIRAL DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 267. GCC ANTIVIRAL DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 268. GCC ANTIVIRAL DRUGS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 269. GCC ANTIVIRAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 270. GCC ANTIVIRAL DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 271. GCC ANTIVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 272. GCC ANTIVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 273. GCC ANTIVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 274. GCC ANTIVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 275. GCC ANTIVIRAL DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 276. GCC ANTIVIRAL DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 277. EUROPEAN UNION ANTIVIRAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 278. EUROPEAN UNION ANTIVIRAL DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 279. EUROPEAN UNION ANTIVIRAL DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 280. EUROPEAN UNION ANTIVIRAL DRUGS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 281. EUROPEAN UNION ANTIVIRAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 282. EUROPEAN UNION ANTIVIRAL DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 283. EUROPEAN UNION ANTIVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 284. EUROPEAN UNION ANTIVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 285. EUROPEAN UNION ANTIVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 286. EUROPEAN UNION ANTIVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 287. EUROPEAN UNION ANTIVIRAL DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 288. EUROPEAN UNION ANTIVIRAL DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 289. BRICS ANTIVIRAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 290. BRICS ANTIVIRAL DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 291. BRICS ANTIVIRAL DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 292. BRICS ANTIVIRAL DRUGS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 293. BRICS ANTIVIRAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 294. BRICS ANTIVIRAL DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 295. BRICS ANTIVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 296. BRICS ANTIVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 297. BRICS ANTIVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 298. BRICS ANTIVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 299. BRICS ANTIVIRAL DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 300. BRICS ANTIVIRAL DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 301. G7 ANTIVIRAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 302. G7 ANTIVIRAL DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 303. G7 ANTIVIRAL DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 304. G7 ANTIVIRAL DRUGS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 305. G7 ANTIVIRAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 306. G7 ANTIVIRAL DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 307. G7 ANTIVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 308. G7 ANTIVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 309. G7 ANTIVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 310. G7 ANTIVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 311. G7 ANTIVIRAL DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 312. G7 ANTIVIRAL DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 313. NATO ANTIVIRAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 314. NATO ANTIVIRAL DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 315. NATO ANTIVIRAL DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 316. NATO ANTIVIRAL DRUGS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 317. NATO ANTIVIRAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 318. NATO ANTIVIRAL DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 319. NATO ANTIVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 320. NATO ANTIVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 321. NATO ANTIVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 322. NATO ANTIVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 323. NATO ANTIVIRAL DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 324. NATO ANTIVIRAL DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 325. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 326. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 327. UNITED STATES ANTIVIRAL DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 328. UNITED STATES ANTIVIRAL DRUGS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 329. UNITED STATES ANTIVIRAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 330. UNITED STATES ANTIVIRAL DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 331. UNITED STATES ANTIVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 332. UNITED STATES ANTIVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 333. UNITED STATES ANTIVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 334. UNITED STATES ANTIVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 335. UNITED STATES ANTIVIRAL DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 336. UNITED STATES ANTIVIRAL DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 337. CANADA ANTIVIRAL DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 338. CANADA ANTIVIRAL DRUGS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 339. CANADA ANTIVIRAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 340. CANADA ANTIVIRAL DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 341. CANADA ANTIVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 342. CANADA ANTIVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 343. CANADA ANTIVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 344. CANADA ANTIVIRAL DRUGS MARKET SIZE, BY DISTRIBUTI